Stock Scorecard



Stock Summary for CASI Pharmaceuticals Inc (CASI) - $2.98 as of 12/30/2024 12:36:09 PM EST

Total Score

8 out of 30

Safety Score

14 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CASI

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CASI

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CASI

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CASI

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CASI (14 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 2
Price to Earnings (Max of 10) 0

Latest News for for CASI

VYNE Therapeutics Inc. ( VYNE ) Reports Q2 Loss, Tops Revenue Estimates 8/14/2024 1:10:00 PM
Ironwood Pharmaceuticals ( IRWD ) Reports Break-Even Earnings for Q2 8/8/2024 12:15:00 PM
Aclaris Therapeutics ( ACRS ) Reports Q2 Loss, Tops Revenue Estimates 8/7/2024 12:15:00 PM
CASI Pharmaceuticals ( NASDAQ:CASI ) Now Covered by StockNews.com 7/10/2024 5:16:00 AM
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP 7/8/2024 11:30:00 AM
CASI Pharmaceuticals ( NASDAQ:CASI ) Now Covered by StockNews.com 7/2/2024 5:20:00 AM
CASI Pharmaceuticals ( CASI ) Up on Buyout Offer for China Business 6/27/2024 1:42:00 PM
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company 6/26/2024 8:15:00 PM
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He 6/26/2024 8:10:00 PM
CASI Pharmaceuticals ( NASDAQ:CASI ) Now Covered by Analysts at StockNews.com 6/24/2024 5:24:00 AM

Financial Details for CASI

Company Overview

Ticker CASI
Company Name CASI Pharmaceuticals Inc
Country China
Description CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and markets therapeutic and pharmaceutical products in China, the United States, and internationally. The company is headquartered in Rockville, Maryland.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2024
Next Earnings Date 3/26/2025

Stock Price History

Last Day Price 2.98
Price 4 Years Ago 29.50
Last Day Price Updated 12/30/2024 12:36:09 PM EST
Last Day Volume 49,484
Average Daily Volume 53,131
52-Week High 8.19
52-Week Low 2.05
Last Price to 52 Week Low 45.37%

Valuation Measures

Trailing PE N/A
Industry PE 21.50
Sector PE 40.21
5-Year Average PE -3.51
Free Cash Flow Ratio 2.79
Industry Free Cash Flow Ratio 11.85
Sector Free Cash Flow Ratio 27.17
Current Ratio Most Recent Quarter 3.20
Total Cash Per Share 1.07
Book Value Per Share Most Recent Quarter 0.67
Price to Book Ratio 3.44
Industry Price to Book Ratio 4.95
Sector Price to Book Ratio 20.56
Price to Sales Ratio Twelve Trailing Months 2.06
Industry Price to Sales Ratio Twelve Trailing Months 81.76
Sector Price to Sales Ratio Twelve Trailing Months 24.58
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 15,461,100
Market Capitalization 46,074,078
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 31.65%
Reported EPS 12 Trailing Months -2.03
Reported EPS Past Year -1.81
Reported EPS Prior Year -2.02
Net Income Twelve Trailing Months -30,349,000
Net Income Past Year -26,938,000
Net Income Prior Year -39,411,000
Quarterly Revenue Growth YOY -59.50%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -240.10%

Balance Sheet

Total Cash Most Recent Quarter 16,537,000
Total Cash Past Year 17,083,000
Total Cash Prior Year 47,112,000
Net Cash Position Most Recent Quarter -1,928,000
Net Cash Position Past Year -1,812,000
Long Term Debt Past Year 18,895,000
Long Term Debt Prior Year 466,000
Total Debt Most Recent Quarter 18,465,000
Equity to Debt Ratio Past Year 0.56
Equity to Debt Ratio Most Recent Quarter 0.43
Total Stockholder Equity Past Year 24,165,000
Total Stockholder Equity Prior Year 44,574,000
Total Stockholder Equity Most Recent Quarter 13,847,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 0
Free Cash Flow Per Share Twelve Trailing Months 0.00
Free Cash Flow Past Year -22,208,000
Free Cash Flow Prior Year -26,700,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.59
MACD Signal -0.59
20-Day Bollinger Lower Band 2.70
20-Day Bollinger Middle Band 5.37
20-Day Bollinger Upper Band 8.03
Beta 0.65
RSI 33.05
50-Day SMA 4.87
150-Day SMA 3.93
200-Day SMA 6.43

System

Modified 12/27/2024 8:20:17 PM EST